CITANEST FORTE DENTAL (prilocaine hydrochloride and epinephrine) injection – prescribing information, methemoglobinemia section (2026)

Government Record · Novocol Pharmaceutical of Canada, Inc.; U.S. National Library of Medicine DailyMed · March 30, 2026

Novocol Pharmaceutical of Canada, 2026-03-30: Prilocaine label warning that methemoglobinemia can occur and is reversed by intravenous methylene blue 1 to 2 mg/kg over five minutes.

Methemoglobinemia can be reversed when indicated by intravenous administration of methylene blue at a dosage of 1 to 2 mg/kg given over a five minute period.

9

Novocol Pharmaceutical of Canada, 2026-03-30: Prilocaine label warning that methemoglobinemia can occur and is reversed by intravenous methylene blue 1 to 2 mg/kg over five minutes. C2. Prilocaine is the local anesthetic named in the claim; its label states cases of methemoglobinemia have been reported with local anesthetic use and names the at-risk groups (G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months, concurrent oxidizing agents). Label also records that the prilocaine metabolite o-toluidine produces methemoglobin. SPL published 2026-03-30; label holder Novocol Pharmaceutical of Canada. DailyMed getFile PDF is the PDF quoted; the drugInfo page carries the same text. Study type: regulatory record.